Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies for genetic diseases, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting held May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein to wild-type levels in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard's sup-tRNAs provided durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The findings underscore the potential of Tevard's platform to address a broad range of genetic diseases caused by premature termination codons. According to the press release, the next-generation sup-tRNAs achieve approximately 100% restoration of full-length dystrophin in DMD models and deliver durable full-length titin rescue in TTN-related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs.
Tevard's suppressor tRNA platform is designed to restore endogenous, full-length protein expression for diseases caused by premature termination codons. The presented programs highlight the versatility of the platform and its ability to restore native protein expression in a cell-specific, durable manner. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information, visit www.tevard.com.
The full announcement, including downloadable images and bios, is available at the provided link. The data were presented at ASGCT 2026, demonstrating the company's progress in developing therapies for genetic diseases with high unmet need.
